

THE LANCET Oncology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Faivre-Finn C, Snee M, Ashcroft L, et al, for the CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. *Lancet Public Health* 2017; published online June 19. [http://dx.doi.org/10.1016/S1470-2045\(17\)30318-2](http://dx.doi.org/10.1016/S1470-2045(17)30318-2).

Web appendix

Details of Recruiting Centres, Numbers of Patients Recruited (N) and Principal Investigators.

UK – 33 Sites

- The Christie NHS Foundation Trust, Manchester (109) – Faivre-Finn
- Edinburgh Cancer Centre (6) – Price
- Bristol Haematology & Oncology Centre (10) – Wilson
- Dorset Cancer Centre, Poole (5) – Laurence
- Torbay Hospital, Devon (2) – Dorey
- Weston Park Hospital, Sheffield (14) – Woll/Hatton
- Lancashire Teaching Hospitals NHS Foundation Trust (15) – Appel
- Cheltenham General Hospital (3) - Guglani
- St James Hospital, Leeds (18) – Snee
- Hammersmith Hospital, London (1) – Mangar
- University College London Hospitals (3) – Carnell
- Beatson West of Scotland Cancer Centre, Glasgow (19) – Mohammed
- Glan Clwyd Hospital, North Wales (10) - Garcia
- Southampton General Hospital (14) – Bhatnagar
- Castle Hill Hospital, Hull (3) – Lind
- James Cook Hospital, Middlesbrough (3) – Peedell
- Northern Ireland Cancer Centre, Belfast City Hospital (10) – McAleese
- Royal Marsden Hospital, Surrey (18) – O’Brien/Locke
- Norfolk & Norwich University Hospital (1) – Roques
- Addenbrooke’s Hospital, Cambridge (15) – Harden
- St Bartholomew’s Hospital, London (3) - Wells
- Raigmore Hospital, Inverness (1) – Macgregor
- Bradford Royal Infirmary (4) – Snee
- Queen Elizabeth Hospital, Birmingham (2) – Chetiyawardana
- Peterborough City Hospital (2) – Fife
- Northern Centre for Cancer Care, Newcastle-upon-Tyne (20) – McMenemin
- Harrogate District NHS Foundation Trust (1) – Chan
- Derriford Hospital, Plymouth (1) – Roy
- The Clatterbridge Cancer Centre, Wirral (3) – Pope
- Charing Cross Hospital & St Mary’s Hospital, London (2) – Lewanski/Power
- Wrexham Maelor Hospital (3) – Garcia
- Ysbyty Gwynedd, Bangor (1) – Ghosal

EORTC - 7 Sites

- Ghent University Hospital, Gent, Belgium (15) – Surmont
- Cliniques Universitaires St Luc, Brussels, Belgium (6) – Geets
- Clinique Sainte Elisabeth, Namur, Belgium (5) – Remouchamps
- The Netherlands Cancer Institute, Amsterdam, The Netherlands (4) – Kneijens
- Arnhem S Radiotherapeutisch Instituut, Arnhem, The Netherlands (5) – Tissing-Tan
- Medical University, Gdansk, Poland (6) – Jassem
- Institute of Oncology, Ljubljana, Slovenia (13) - Zwitter

SPAIN – 6 Sites

- Institut Català d’Oncologia, Hospital Duran i Reynals, L’Hospitalet (12) – Cardenal
- Institut Català d’Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona (2) – Jove/Carcereny
- University Hospital Ramon y Cajal, Madrid (1) – Hernanz
- Hospital de la Santa Creu i Sant Pau, Barcelona (6) – Majem/Farre
- Institut Oncològic del Vallès (IOV), Barcelona (3) – Solé Monné

- Corporació Sanitària Parc Taulí de Sabadell, Barcelona (3) – Solé Monné/García García

FRANCE – 19 Sites

- Institut de Cancérologie Lucien Neuwirth (2) – Fournel
- Centre Léon Bérard (CLB) (5) – Martel-Lafay
- Hôpital de la Croix-Rousse, Lyon (3) – Arpin
- CHU de Limoges (2) – Vergnenègre/Clavère
- CH de Villefranche/Saône (2) – Falchero
- Centre François Baclesse, Caen (4) – Gervais/Le Rouge
- CH de Aix en Provence (1) – Le Treut
- Institut Ste Catherine, Avignon (12) – Pourel
- CHI de Creteil (6) – Monnet/Martin
- CHU de Clermont-Ferrand (5) – Janicot
- HIA Toulon (1) – Bérard
- Gustave Roussy Cancer Campus, Villejuif (18) – Le Pechoux
- Centre Georges François Leclerc Dijon (5) – Peignaux/Coudert
- Assistance Publique Hôpitaux de Marseille (21) – Padovani/Barlesi
- CHU de Rennes (3) – Lena
- CHU de Caen (2) – Zalcman
- CHU de Lille (6) – Lafitte
- Centre Oscar Lambret, Lille (3) – Prevost
- CH de Libourne (2) – Abdiche

CANADA - 9 Sites

- CHUQ-Pavillon Hotel-Dieu de Quebec, Quebec City (4) – Dagnault
- Cancer Center of SE Ontario at Kingston (5) – de Metz
- Ottawa Hospital Research Institute (13) – Pantarotto
- Princess Margaret Cancer Center, Toronto (7) – Bezjak
- Allan Blair Cancer Center, Regina (2) – Koul
- Saskatoon Cancer Center (1) - Kundapur
- Cancer Care Manitoba (4) – Leylek
- Juravinski Cancer Center (4) – Okawara
- London Regional Cancer Program (1) – Yaremko

Web appendix - Acute adverse events (up to 3 months after completion of study treatment)

| AE CTCAE v3.0 | Group | 0 N (%) | 1-2 N (%) | 3-5 N (%) | P** Grade 3-5 |
|---------------------|-------|------------|--------------|------------------------|------------------|
| Nausea | BD | 70 (26.4) | 172 (64.9) | 23 (8.7) | 0.63 |
| | OD | 66 (25.1) | 171 (65.1) | 26 (9.9) | |
| Vomiting | BD | 146 (55.3) | 105 (39.7) | 13 (4.9) | 0.99 |
| | OD | 155 (59.0) | 95 (36.1) | 13 (4.9) | |
| Mucositis | BD | 173 (65.5) | 88 (33.4) | 3 (1.1) | 0.34 |
| | OD | 169 (64.5) | 87 (33.2) | 6 (2.3) | |
| Fatigue | BD | 21 (8.0) | 212 (80.3) | 31 (11.7) | 0.77 |
| | OD | 13 (5.0) | 216 (82.4) | 33 (12.6) | |
| Neuropathy-motor | BD | 250 (94.3) | 12 (4.5) | 1 (0.4) | 0.62 |
| | OD | 245 (93.5) | 15 (5.8) | 2 (0.8) | |
| Neuropathy-sensory | BD | 196 (74.5) | 63 (24.0) | 4 (1.5) | >0.99 |
| | OD | 197 (74.9) | 61 (23.2) | 5 (1.9) | |
| Infection | BD | 187 (70.8) | 43 (16.3) | 34 (12.9) | 0.52 |
| | OD | 181 (69.1) | 52 (19.9) | 29 (11.0) | |
| Anorexia | BD | 111 (42.0) | 135 (51.2) | 18 (6.8) | 0.60 |
| | OD | 112 (42.8) | 129 (49.2) | 21 (8.0) | |
| Other ⁺ | BD | 37 (14.7) | 150 (57.4) | 76 (28.9)* | 0.02 |
| | OD | 33 (12.6) | 177 (67.6) | 52 (19.9) | |
| Haemoglobin | BD | 39 (14.7) | 194 (72.9) | 33 (12.4) | 0.72 |
| | OD | 41 (15.7) | 184 (70.8) | 35 (13.5) | |
| Neutrophils | BD | 31 (11.7) | 38 (13.7) | 197 (74.1) | 0.03 |
| | OD | 43 (16.5) | 47 (18.1) | 170 (65.4) | |
| Febrile neutropenia | BD | 203 (76.6) | NA | 62 (23.4) | 0.13 |
| | OD | 214 (82.0) | | 47 (18.0) [#] | |
| Platelets | BD | 132 (49.6) | 89 (33.5) | 45 (16.9) | 0.26 |
| | OD | 119 (45.8) | 87 (33.4) | 54 (20.8) | |
| Oesophagitis | BD | 48 (18.9) | 159 (62.6) | 47 (18.5) | 0.85 |
| | OD | 63 (25.7) | 135 (55.1) | 47 (19.2) | |
| Pneumonitis | BD | 198 (78.0) | 51 (20.1) | 5 (2.0)~ | 0.70 |
| | OD | 187 (77.3) | 49 (20.2) | 6 (2.4)~ | |

BD – twice-daily

OD – once-daily

⁺ ‘Other’ grade 3 reported toxicities included:

For OD arm, diarrhoea, hyponatremia, urinary retention and dysphagia and lymphopenia

For BD arm, diarrhoea, constipation, hyponatremia, dysphagia, lymphopenia, dyspnoea and leukopenia

* 2 grade 5 (peripheral arterial ischaemia and 1 septic shock)

[#] 1 grade 5

~ 3 grade 5 (2 in the once-daily arm & 1 in the twice-daily arm)

**p values are calculated using chi-square tests

Web appendix – Post-Progression Treatment Data

| | Twice-daily radiotherapy N=153* | Once-daily radiotherapy N=139* |
|---------------------|---|--|
| Chemotherapy | 88 (58%) | 82 (59%) |
| Radiotherapy | 42 (27%) | 33 (24%) |
| Surgery | 8 (5%) | 8 (6%) |
| Other | 19 (12%) | 12 (9%) |

*Figures provided from the group of patients who progressed after initial chemo-radiotherapy. The denominators are the number of progressors and the figures are marginal i.e. there may be overlap e.g. chemotherapy + radiotherapy etc.